[ad_1]
FILE PHOTO: A booth displaying a coronavirus vaccine candidate from China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), is seen at the China International Trade Fair for Services 2020 (CIFTIS), following the COVID-19 outbreak, in Beijing, China, on September 4, 2020. REUTERS / Tingshu Wang / File Photo
BEIJING / SINGAPORE – A vaccine developed by a unit of the China National Biotec Group (CNBG) is 79.34% effective in protecting people from COVID-19 and the company is seeking regulatory approval for public use in China, the developer said Wednesday.
The efficacy rate, based on an interim analysis of phase 3 clinical trials, is lower than the 86% rate for the same vaccine announced by the United Arab Emirates on December 9, according to preliminary data from trials there. .
A company spokeswoman declined to explain the discrepancy, saying detailed results would be released later, without giving a deadline.
There have been fragmentary releases of efficacy data for COVID-19 candidate Chinese vaccine manufacturers, which are being considered by many developing countries for mass inoculation campaigns.
Health experts warn that the different results could undermine confidence in these vaccines.
Turkish researchers said Thursday that their interim result on a COVID-19 vaccine developed by China’s Sinovac Biotech showed an efficacy of 91.25% only to see a confusing same-day reading from Brazil that said the vaccine’s efficacy was between 50% and 90%.
The CNBG vaccine is among China’s five most advanced candidates in terms of development and has been used in the country’s emergency use program that has vaccinated hundreds of thousands of people since July.
The CNBG unit, called the Beijing Biological Products Institute, said in a statement that the efficacy rate is based on an interim analysis of data from its Phase 3 trials and that it had applied for conditional approval of the vaccine from the National Administration. of Medical Products.
It did not provide details such as the number of infections in the trial, what side effects, if any, it identified, how many volunteers have given the vaccine or a placebo.
CNBG, a subsidiary of the state-backed China National Pharmaceutical Group (Sinopharm), has another vaccine in late-stage trials and both have been approved for emergency use in China even though studies have not been completed.
/ MUF
For more news on the new coronavirus, click here.
What you need to know about the coronavirus.
For more information on COVID-19, call the DOH hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our leaders in healthcare and still accepts cash donations to be deposited into the Banco de Oro (BDO) checking account # 007960018860 or donate through PayMaya using this link .
Read next
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer and more than 70 other titles, share up to 5 gadgets, listen to the news, download from 4am and share articles on social media. Call 896 6000.
For comments, complaints or inquiries, please contact us.
[ad_2]
